Brepocitinib (Lisraya) Becomes the First Oral Treatment Approved for Dermatomyositis

Dermatomyositis is an inflammatory muscle disease driven by autoimmunity — specifically, by type I interferon signaling gone wrong. The hallmark is proximal muscle weakness combined with characteristic skin findings: heliotrope rash around the eyes, Gottron papules over the knuckles, V-sign and shawl sign rashes on the chest and back. It is rare — affecting roughly 10 per 100,000 — but it is serious: patients lose the ability to climb stairs, raise their arms above their head, and eventually swallow. Many develop interstitial lung disease. And until this week, there was no FDA-approved oral treatment. The standard of care has been systemic corticosteroids, which work initially but cause toxicity with prolonged use, combined with immunosuppressants like azathioprine or mycophenolate that work through non-targeted broad immune suppression.[1]

Brepocitinib (Lisraya) changes that picture. The FDA approved it on August 27, 2026 for adults with dermatomyositis — the first oral disease-specific treatment for this condition in history. Its mechanism is a dual inhibition of TYK2 (tyrosine kinase 2) and JAK1. TYK2 is particularly relevant because it transduces type I interferon signaling — the same interferon pathway that appears to be the key driver of dermatomyositis pathogenesis, as evidenced by the elevated interferon gene expression signatures found in muscle biopsies and skin of affected patients. JAK1 inhibition additionally dampens IL-12 and IL-23 signaling, which drives downstream inflammatory cascades in muscle and skin.[1,2]

The VALOR phase 3 trial, led by Ruth Ann Vleugels at Harvard and published in the New England Journal of Medicine in March 2026, randomized patients with active dermatomyositis to brepocitinib or placebo on top of standard background therapy. The primary endpoint was the Total Improvement Score (TIS) — a composite validated measure that assesses muscle enzymes, muscle strength, physician and patient global assessments, and functional ability. Brepocitinib met the primary endpoint and all 9 pre-specified secondary endpoints, including measures of muscle strength, skin disease activity, and patient-reported function.[1]

Mechanism and Disease Biology

The interferon-driven pathogenesis of dermatomyositis has been understood at a mechanistic level for over a decade. Plasmacytoid dendritic cells flood muscle and skin, producing massive quantities of type I interferons. These interferons upregulate a downstream gene expression program — the "interferon signature" — that drives inflammation, myofiber damage, and perifascicular atrophy (the pathognomonic pattern on muscle biopsy). TYK2 sits at the top of this pathway: it is activated by type I interferons and propagates their signal into the nucleus via STAT1 and STAT2. Blocking TYK2 therefore strikes near the source of the pathology, rather than suppressing immune function broadly the way conventional immunosuppressants do.[1,3]

JAK1 inhibition is an additional mechanism. JAK1 mediates signaling from multiple cytokine receptors relevant to dermatomyositis, including IL-6 (which promotes inflammation), IL-12 and IL-23 (which drive Th1/Th17 responses), and interferons. The dual TYK2/JAK1 profile of brepocitinib is distinct from selective JAK3 or JAK2 inhibitors used in other conditions: it is tailored to the cytokine milieu most relevant to dermatomyositis. Brepocitinib is dosed orally once daily — a substantial practical advantage over intravenous immunosuppressants and over biologics like IVIG or rituximab that require infusion center visits.

Why It Matters Clinically

The drug's approval does not eliminate the challenges of managing dermatomyositis — the disease is heterogeneous, and patients with anti-MDA5 antibody-associated dermatomyositis (which carries high ILD risk) or amyopathic dermatomyositis were likely underrepresented in VALOR. The safety class effects of JAK inhibitors — infection risk (including herpes zoster), cytopenia, and cardiovascular signals identified in large RA populations — will apply here and require monitoring. The FDA approval label will specify a REMS or risk communication requirement consistent with the JAK inhibitor class safety profile.

For patients, the oral route and the evidence of improvement across skin, muscle, and function make brepocitinib a meaningful advance. Dermatomyositis profoundly affects quality of life — the combination of visible skin rash (often the presenting concern for younger patients) and progressive muscle weakness limits not just work and activities of daily living, but also social participation and identity. An effective oral treatment backed by rigorous randomized evidence represents what clinical trial design, mechanistic understanding, and pharmaceutical development are supposed to deliver.

Limitations

VALOR enrolled active dermatomyositis; efficacy in amyopathic dermatomyositis (skin only, no muscle involvement) or anti-synthetase syndrome was not separately demonstrated. JAK inhibitor class safety signals (venous thromboembolism, major cardiovascular events, malignancy) from larger RA/IBD populations require monitoring in this indication. Long-term durability of response beyond the trial follow-up period is not yet established. The drug was studied on top of background corticosteroids and immunosuppressants — not as monotherapy. ILD outcomes were not a primary or key secondary endpoint.